CN109715658B - 可溶性成纤维细胞生长因子受体3(sfgfr3)多肽及其用途 - Google Patents

可溶性成纤维细胞生长因子受体3(sfgfr3)多肽及其用途 Download PDF

Info

Publication number
CN109715658B
CN109715658B CN201780049433.8A CN201780049433A CN109715658B CN 109715658 B CN109715658 B CN 109715658B CN 201780049433 A CN201780049433 A CN 201780049433A CN 109715658 B CN109715658 B CN 109715658B
Authority
CN
China
Prior art keywords
sfgfr3
polypeptide
seq
del4
fgfr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780049433.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN109715658A (zh
Inventor
埃尔维雷·古兹
斯特凡妮·加西亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blue Coast University
French Institute Of Health And Medicine
Tera Sean Holdings Ltd
Therachon
Pfizer Inc
Original Assignee
Blue Coast University
French Institute Of Health And Medicine
Therachon
Université Côte d'Azur
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blue Coast University, French Institute Of Health And Medicine, Therachon, Université Côte d'Azur, Pfizer Inc filed Critical Blue Coast University
Publication of CN109715658A publication Critical patent/CN109715658A/zh
Application granted granted Critical
Publication of CN109715658B publication Critical patent/CN109715658B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201780049433.8A 2016-07-07 2017-07-07 可溶性成纤维细胞生长因子受体3(sfgfr3)多肽及其用途 Expired - Fee Related CN109715658B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662359607P 2016-07-07 2016-07-07
US62/359,607 2016-07-07
US201762467478P 2017-03-06 2017-03-06
US62/467,478 2017-03-06
PCT/EP2017/067119 WO2018007597A1 (en) 2016-07-07 2017-07-07 Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
CN109715658A CN109715658A (zh) 2019-05-03
CN109715658B true CN109715658B (zh) 2023-09-12

Family

ID=59381265

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780049433.8A Expired - Fee Related CN109715658B (zh) 2016-07-07 2017-07-07 可溶性成纤维细胞生长因子受体3(sfgfr3)多肽及其用途

Country Status (20)

Country Link
US (3) US10294289B2 (enExample)
EP (2) EP3481859B1 (enExample)
JP (2) JP7046903B2 (enExample)
KR (2) KR102432192B1 (enExample)
CN (1) CN109715658B (enExample)
AU (2) AU2017294551B2 (enExample)
BR (1) BR112019000257A2 (enExample)
CA (1) CA3029877C (enExample)
DK (1) DK3481859T3 (enExample)
ES (1) ES2912559T3 (enExample)
HU (1) HUE058734T2 (enExample)
IL (1) IL264030A (enExample)
MX (1) MX2018016257A (enExample)
PL (1) PL3481859T3 (enExample)
PT (1) PT3481859T (enExample)
RU (1) RU2751483C2 (enExample)
SG (1) SG11201900074WA (enExample)
SI (1) SI3481859T1 (enExample)
WO (1) WO2018007597A1 (enExample)
ZA (1) ZA201900507B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150344855A1 (en) 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
KR102432192B1 (ko) 2016-07-07 2022-08-12 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도
EP3684394A1 (en) * 2017-09-20 2020-07-29 Pfizer Inc. Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides
WO2020243478A1 (en) * 2019-05-29 2020-12-03 Massachusetts Eye And Ear Infirmary Fibroblast growth factor 2 (fgf2) for treatment of human sensorineural hearing loss
US11625937B2 (en) * 2020-04-06 2023-04-11 Toyota Motor Engineering & Manufacturing North America, Inc. Methods and systems for monitoring human body weight with vehicle sensors and big data AI analytics
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
JP2022184798A (ja) 2021-06-01 2022-12-13 ファイザー・インク ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
KR20250162619A (ko) 2023-03-20 2025-11-18 아센디스 파마 그로우쓰 디스오더스 에이/에스 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법
CN116284327A (zh) * 2023-03-28 2023-06-23 中国药科大学 一种靶向肿瘤的成纤维细胞生长因子19的重组蛋白及其应用
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
CN121537499B (zh) * 2026-01-22 2026-05-08 中国科学院苏州纳米技术与纳米仿生研究所 一种来源于人β防御素-3的仿生肽及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017198A2 (en) * 2008-08-04 2010-02-11 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
CN105121464A (zh) * 2013-01-16 2015-12-02 法国健康和医学研究院 用于预防或治疗骨骼生长迟缓病症的可溶性成纤维细胞生长因子受体3(fgr3)多肽

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
WO1996041523A1 (en) 1995-06-12 1996-12-27 Yeda Research And Development Co., Ltd. Fgf9 as a specific ligand for fgfr3
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US20040109850A1 (en) 2000-12-18 2004-06-10 Neelam Jaiswal Treatment of bone disorders by modulation of fgfr3
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
JP2003104908A (ja) 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
AU2005216547B2 (en) 2004-02-24 2009-03-12 Allergan, Inc. Botulinum toxin screening assays
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
US8962556B2 (en) 2006-09-28 2015-02-24 Prochon Biotech Ltd. FGF-2 variants having N-terminal deletions and increased receptor selectivity and uses thereof
WO2008133873A2 (en) 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
WO2010002862A2 (en) 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
ES2549769T3 (es) * 2009-03-25 2015-11-02 Genentech, Inc. Anticuerpos anti-FGFR3 y métodos que emplean los mismos
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
PT2498799T (pt) 2009-11-13 2016-11-04 Five Prime Therapeutics Inc Utilização de proteínas do domínio extracelular rfcf1 para tratar cancros caracterizados por mutações ativadoras dependentes de ligando em rfcf2
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
WO2011088196A2 (en) 2010-01-14 2011-07-21 Yale University Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
CN102219860B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CA2853358A1 (en) 2011-10-24 2013-05-02 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
CA2880013C (en) 2012-07-24 2022-11-29 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
BR112015001724A2 (pt) 2012-07-27 2018-04-03 Genentech Inc métodos de tratamento de condições relacionadas a fgfr3
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
CA2972865A1 (en) 2015-01-07 2016-07-14 Therachon Sas Soluble fgfr3 decoys for treating skeletal growth disorders
KR102432192B1 (ko) 2016-07-07 2022-08-12 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도
EP3684394A1 (en) 2017-09-20 2020-07-29 Pfizer Inc. Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017198A2 (en) * 2008-08-04 2010-02-11 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
CN105121464A (zh) * 2013-01-16 2015-12-02 法国健康和医学研究院 用于预防或治疗骨骼生长迟缓病症的可溶性成纤维细胞生长因子受体3(fgr3)多肽

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FGFR3突变与软骨发育不全的研究进展;张明等;《中国优生与遗传杂志》;20101231;第18卷(第5期);全文 *

Also Published As

Publication number Publication date
ES2912559T3 (es) 2022-05-26
US11697678B2 (en) 2023-07-11
EP3481859A1 (en) 2019-05-15
JP2022096660A (ja) 2022-06-29
PL3481859T3 (pl) 2022-07-11
SG11201900074WA (en) 2019-02-27
JP7046903B2 (ja) 2022-04-04
RU2751483C2 (ru) 2021-07-14
US10294289B2 (en) 2019-05-21
EP4122955A1 (en) 2023-01-25
JP7348980B2 (ja) 2023-09-21
HUE058734T2 (hu) 2022-09-28
RU2019100381A3 (enExample) 2020-11-23
EP3481859B1 (en) 2022-04-13
KR102432192B1 (ko) 2022-08-12
RU2019100381A (ru) 2020-08-11
ZA201900507B (en) 2023-04-26
CN109715658A (zh) 2019-05-03
SI3481859T1 (sl) 2022-07-29
KR20190037240A (ko) 2019-04-05
MX2018016257A (es) 2019-11-21
US11021528B2 (en) 2021-06-01
AU2022202906A1 (en) 2022-05-26
CA3029877A1 (en) 2018-01-11
WO2018007597A1 (en) 2018-01-11
AU2017294551B2 (en) 2022-03-03
US20210309718A1 (en) 2021-10-07
AU2017294551A1 (en) 2019-01-31
CA3029877C (en) 2023-07-25
US20180230197A1 (en) 2018-08-16
DK3481859T3 (da) 2022-04-25
IL264030A (en) 2019-01-31
JP2019527053A (ja) 2019-09-26
PT3481859T (pt) 2022-05-23
KR20220122762A (ko) 2022-09-02
US20200190162A1 (en) 2020-06-18
BR112019000257A2 (pt) 2019-10-01

Similar Documents

Publication Publication Date Title
JP7348980B2 (ja) 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用
ES2969528T3 (es) Mutantes de FGF21 y usos de los mismos
US20210009657A1 (en) Soluble fgfr3 decoys for treating skeletal growth disorders
JP7597398B2 (ja) 組換え神経成長因子のための組成物及び方法
JP7335247B2 (ja) 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置
WO2006029094A2 (en) Erythropoietin derivatives with altered immunogenicity
AU2014206844A1 (en) A soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
JP6820123B2 (ja) Ｃｃｌ３変異体を含む融合タンパク質およびその用途
NZ790135A (en) Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
HK40050674A (en) Soluble fgfr3 decoys for treating skeletal growth disorders
HK40039240A (en) Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides
HK1246313B (en) Soluble fgfr3 decoys for treating skeletal growth disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200623

Address after: New York, USA

Applicant after: PFIZER Inc.

Applicant after: French Institute of Health and Medicine

Applicant after: Blue Coast University

Address before: Basel, Switzerland

Applicant before: Tera Sean Holdings Ltd.

Applicant before: French Institute of Health and Medicine

Applicant before: Blue Coast University

Effective date of registration: 20200623

Address after: Basel, Switzerland

Applicant after: Tera Sean Holdings Ltd.

Applicant after: French Institute of Health and Medicine

Applicant after: Blue Coast University

Address before: Fa Guowaerbang

Applicant before: THERACHON

Applicant before: French Institute of Health and Medicine

Applicant before: Blue Coast University

Effective date of registration: 20200623

Address after: Fa Guowaerbang

Applicant after: THERACHON

Applicant after: French Institute of Health and Medicine

Applicant after: Blue Coast University

Address before: Fa Guobiao

Applicant before: THERACHON

Applicant before: French Institute of Health and Medicine

Applicant before: University NICE SOPHIA ANTIPOLIS

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20230912